The anti-fibrotic agent, tipelukast (MN-001) reduces serum triglyceride significantly in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients with hypertriglyceridemia after 4 weeks of treatment, an interim analysis of ongoing clinical trial, MN-001-NATG-201

The anti-fibrotic agent, tipelukast (MN-001) reduces serum triglyceride significantly in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients with hypertriglyceridemia after 4 weeks of treatment, an interim analysis of ongoing clinical trial, MN-001-NATG-201

Saved in:
Bibliographic Details
Published in:Journal of hepatology Vol. 68; p. S586
Main Authors: Matsuda, K., Gutierrez, J., Hassanein, T., Iwaki, Y.
Format: Journal Article
Language:English
Published: 01-04-2018
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0168-8278
DOI:10.1016/S0168-8278(18)31433-8